Conmed Corp.’s recent filing unveils that its Director BRONSON DAVID M acquired Company’s shares for reported $97322.0 on May 13 ’24. In the deal valued at $72.09 per share,1,350 shares were bought. As a result of this transaction, BRONSON DAVID M now holds 16,460 shares worth roughly $1.23 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Schwarzentraub Barbara J bought 1,442 shares, generating $99,873 in total proceeds. Upon buying the shares at $69.26, the Director now owns 1,442 shares.
Before that, Aronson Martha Goldberg bought 2,000 shares. Conmed Corp. shares valued at $141,960 were divested by the Director at a price of $70.98 per share. As a result of the transaction, Aronson Martha Goldberg now holds 2,000 shares, worth roughly $0.15 million.
Needham reiterated its Conmed Corp. [CNMD] rating to a Buy in a research note published on February 01, 2024; the price target was $129. A number of analysts have revised their coverage, including CL King’s analysts, who began to cover the stock in late May with a ‘”a Buy”‘ rating. KeyBanc Capital Markets also remained covering CNMD and has increased its forecast on March 27, 2023 with a “an Overweight” recommendation from previously “Sector weight” rating. Wells Fargo started covering the stock on March 21, 2023. It rated CNMD as “an Equal weight”.
Price Performance Review of CNMD
On Tuesday, Conmed Corp. [NYSE:CNMD] saw its stock fall -0.60% to $74.86. Over the last five days, the stock has gained 3.30%. Conmed Corp. shares have fallen nearly -31.64% since the year began. Nevertheless, the stocks have fallen -37.07% over the past one year. While a 52-week high of $138.47 was reached on 01/12/24, a 52-week low of $61.05 was recorded on 04/25/24. SMA at 50 days reached $74.59, while 200 days put it at $94.31. A total of 0.39 million shares were traded, compared to the trading of 0.32 million shares in the previous session.
Levels Of Support And Resistance For CNMD Stock
The 24-hour chart illustrates a support level at 74.25, which if violated will result in even more drops to 73.63. On the upside, there is a resistance level at 75.52. A further resistance level may holdings at 76.17. The Relative Strength Index (RSI) on the 14-day chart is 55.06, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 2.44, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 17.07%. Stochastics %K at 85.21% indicates the stock is a selling.
The most recent change occurred on October 12, 2022 when Jefferies began covering the stock and recommended ‘”a Hold”‘ rating along with a $85 price target.
